Caris Life Sciences, Inc. (NASDAQ: CAI) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
22.96
+0.22+0.98%
TA
Loading chart...
Snapshot
| Index | - | P/E | 61.15 | EPS (ttm) | 0.37 | Insider Own | - | Shs Outstand | 282.68M | Perf Week | 45.12% |
| Market Cap | 6.43B | Forward P/E | 64.76 | EPS next Y | 0.35 | Insider Trans | 0.05% | Shs Float | 11.29M | Perf Month | 27.25% |
| Enterprise Value | 6.19B | PEG | 0.23 | EPS next Q | - | Inst Own | - | Short Float | 4.15% | Perf Quarter | 14.62% |
| Income | 104.78M | P/S | 6.50 | EPS this Y | 107.10% | Inst Trans | - | Short Ratio | 4.05 | Perf Half Y | 7.01% |
| Sales | 989.60M | P/B | 10.87 | EPS next Y | 227.32% | ROA | 8.55% | Short Interest | 11.73M | Perf YTD | -15.72% |
| Book/sh | - | P/C | 31.94 | EPS next 5Y | 76.46% | ROE | 18.77% | 52W High | 42.91 -46.49% | Perf Year | -21.45% |
| Cash/sh | - | P/FCF | 43.88 | EPS past 3/5Y | - | ROIC | 14.67% | 52W Low | 14.33 60.25% | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | 37.25 | Sales past 3/5Y | 46.55% 22.53% | Gross Margin | 69.66% | Volatility | 7.74% 5.86% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 6.25 | EPS Y/Y TTM | 44.07% | Oper. Margin | 15.49% | ATR (14) | 1.21 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.88 | Sales Y/Y TTM | 120.15% | Profit Margin | 10.62% | RSI (14) | 78.62 | Recom | 2.14 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.53 | EPS Q/Q | -100.64% | SMA20 | 36.80% | Beta | 1.39 | Target Price | 25.50 |
| Payout | 0.00% | Debt/Eq | 0.76 | Sales Q/Q | 78.51% | SMA50 | 32.56% | Rel Volume | 2.54 | Prev Close | 22.74 |
| Employees | 1,846 | LT Debt/Eq | 0.66 | Earnings | Nov 04 | SMA200 | 6.64% | Avg Volume | 3.69M | Price | 22.96 |
| IPO Date | Jun 18, 2025 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 92.53% 3.23% | Net Debt/EBITDA | -1.44 | Volume | 9,363,579 | Change | 0.98% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-07-26 | Reiterated | BTIG | Buy | $32 → $33 |
| Aug-06-26 | Reiterated | Evercore ISI Group | Outperform | $25 → $26 |
| Jul-06-26 | Reiterated | Evercore ISI Group | Outperform | $38 → $25 |
| May-08-26 | Reiterated | Robert W. Baird | $28 → $22 | |
| May-08-26 | Reiterated | BTIG | Buy | $45 → $32 |
| Apr-10-26 | Initiated | Piper Sandler | Neutral | $21 |
| Feb-17-26 | Initiated | Baird | Outperform | $26 |
| Jan-05-26 | Reiterated | Evercore ISI | Outperform | $40 → $38 |
| Dec-22-25 | Reiterated | Canaccord Genuity | Hold | $28 → $30 |
| Dec-02-25 | Initiated | Canaccord | Hold | $28 |
Latest News
Aug-06-26
Aug-05-26
07:04PM
Caris Life Sciences Q2 Earnings Call Highlightsmarketbeat.com
04:05PM
Jul-21-26
Jul-21-2604:28PM
05:29AM
Jul-16-26
Jul-16-2608:30AM
Jul-14-26
Jul-14-2608:36AM
08:30AM
Jul-10-26
Jul-02-26
Jul-01-26
Jul-01-2608:30AM
Jun-22-26
Jun-19-26
Company
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | FY 2017 12/31/2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 990 | 812 | 412 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 300 | 273 | 233 | — | — | — | — | — | — | |
| Gross Profit | 690 | 539 | 179 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 419 | 392 | 322 | — | — | — | — | — | — | |
| Research and Development | 91 | 45 | 114 | — | — | — | — | — | — | |
| Other Operating Expense | 27 | 57 | 0 | — | — | — | — | — | — | |
| Operating Income | 153 | 45 | -257 | — | — | — | — | — | — | |
| Interest Expense | 47 | 57 | 50 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -1 | -56 | 25 | — | — | — | — | — | — | |
| Net Income Before Taxes | 104 | -68 | -282 | — | — | — | — | — | — | |
| Income Taxes | 0 | 470 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | 104 | -538 | -282 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 104 | -538 | -282 | — | — | — | — | — | — | |
| Net Income | 104 | -538 | -282 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.37 | -1.91 | -2.70 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.37 | -1.91 | -2.70 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.36 | -1.86 | -2.70 | — | — | — | — | — | — | |
| EBITDA | 167 | 11 | -183 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 63.78 | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 6.56 | 9.37 | — | — | — | — | — | — | — | |
| Gross Margin | 69.70 | 66.38 | 43.45 | — | — | — | — | — | — | |
| Operating Margin | 15.45 | 5.54 | -62.38 | — | — | — | — | — | — | |
| Net Margin | 10.51 | -66.26 | -68.45 | — | — | — | — | — | — | |
| Shares Outstanding | 283 | 282 | 255 | — | — | — | — | — | — | |
| Market Capitalization | 6,498 | 7,608 | — | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| HALBERT JON | Director | May 15 '26 | Buy | 14.56 | 68,000 | 990,080 | 704,598 | Jul 13 |
| Vacirca Jeff L | Director | May 11 '26 | Buy | 16.15 | 31,050 | 501,426 | 49,671 | May 12 |
| CASTLEMAN PETER M | Director | Jan 09 '26 | Option Exercise | 18.60 | 2,500 | 46,500 | 18,629 | Jan 13 |
| Power Luke Thomas | See Remarks | Dec 11 '25 | Option Exercise | 2.44 | 62,250 | 151,890 | 161,821 | Dec 12 |
| Power Luke Thomas | See Remarks | Dec 11 '25 | Sale | 26.58 | 62,250 | 1,654,462 | 99,571 | Dec 12 |
| Spetzler David Baxley | President | Nov 07 '25 | Buy | 23.85 | 400 | 9,540 | 460,777 | Nov 10 |
| Denton John Russel | See Remarks | Nov 07 '25 | Buy | 24.09 | 4,184 | 100,793 | 9,184 | Nov 10 |
| PHILLIPS T DANNY | Director | Sep 11 '25 | Option Exercise | 2.44 | 100,000 | 244,000 | 116,129 | Sep 12 |
| POSTE GEORGE | Director | Aug 11 '25 | Option Exercise | 2.44 | 250,000 | 610,000 | 359,754 | Aug 13 |
| TSSP Sub-Fund HoldCo LLC | other: Former 10% Owner | Jun 20 '25 | Option Exercise | 1.34 | 5,429,629 | 7,297,975 | 5,687,176 | Jun 23 |
| Spetzler David Baxley | President | Jun 20 '25 | Option Exercise | 2.44 | 75,000 | 183,000 | 558,668 | Jun 23 |
| Denton John Russel | See Remarks | Jun 20 '25 | Buy | 21.00 | 7,500 | 157,500 | 123,591 | Jun 23 |
| Brille Brian J | See Remarks | Jun 20 '25 | Buy | 21.00 | 30,000 | 630,000 | 162,428 | Jun 23 |
| Sawka Gary | Director | Jun 01 '21 | Option Exercise | 21.62 | 10,000 | 216,200 | 33,912 | Jun 03 |
| Sawka Gary | Director | Jun 02 '20 | Option Exercise | 13.48 | 10,000 | 134,800 | 23,321 | Jun 04 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.